Fujifilm partners for Avigan ex-Japan

2 July 2020

As drug and vaccine developers are scrambling to scale up production and marketing of potential COVID-19 therapies, a unit of Japan’s Fujifilm Corp (TYO: 4901) has signed a major collaboration on the development, manufacture and sales of its anti-influenza virus drug Avigan (favipiravir).

A tripartite licensing agreement has been concluded between Fujifilm Toyama Chemical, India’s Dr Reddy’s Laboratories (BSE: 500124), and Global Response Aid (GRA), concerning the development, manufacture and sales of Avigan, which is a potential drug for a treatment of COVID-19.

However, Japan’s Health Minister Katsunobu Kato revealed on May 26 that his ministry has given up on the government’s end-May target for approving Avigan for the treatment of COVID-19 as sufficient data to support its efficacy are not yet available.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK